Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Yuhuan, Gao"'
Autor:
Zhongjun Xia, Yun Leng, Baijun Fang, Yang Liang, Wei Li, Chengcheng Fu, Linhua Yang, Xiaoyan Ke, Hua Jiang, Jianyu Weng, Li Liu, Yaozhong Zhao, Xuejun Zhang, Zhongxia Huang, Aichun Liu, Qingzhi Shi, Yuhuan Gao, Xiequn Chen, Ling Pan, Zhen Cai, Zhao Wang, Yafei Wang, Yaqun Fan, Ming Hou, Yigai Ma, Jianda Hu, Jing Liu, Jianfeng Zhou, Xiaohong Zhang, Haitao Meng, Xuzhang Lu, Fei Li, Hanyun Ren, Bintao Huang, Zonghong Shao, Hebing Zhou, Yu Hu, Shifang Yang, Xiangjun Zheng, Peng Wei, Hongyan Pang, Wei Yu, Yuzhang Liu, Sujun Gao, Lingzhi Yan, Yanping Ma, Hongmei Jing, Juan Du, Wei Ling, Jingyi Zhang, Weiwei Sui, Fuxu Wang, Xin Li, Wenming Chen
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in p
Externí odkaz:
https://doaj.org/article/b54d9a34e0c7454a9a0589390ee8abee
Autor:
Kaili Zhong, Yanyan Shi, Yuhuan Gao, Huilai Zhang, Mingzhi Zhang, Qiaohua Zhang, Xinan Cen, Mei Xue, Yan Qin, Yu Zhao, Liling Zhang, Rong Liang, Ningju Wang, Yan Xie, Yu Yang, Aichun Liu, Huizheng Bao, Jingwen Wang, Baoping Cao, Wei Zhang, Weijing Zhang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background This study aimed to compare the efficacy and safety of high-dose methotrexate (HD-MTX) versus teniposide (TEN) in patients with newly diagnosed immunocompetent primary central nervous system lymphomas (PCNSLs). Methods The study i
Externí odkaz:
https://doaj.org/article/e64212ebe785499289b5056df637f01c
Autor:
Zhong Zheng, Huilai Zhang, Keshu Zhou, Hui Zhou, LI Zhang, Caixia LI, Min Zhou, Wenbin Qian, Zhiming LI, Qingyuan Zhang, Ying Cheng, Liu Peng, Zhenyu LI, Liping Su, Fei LI, Xiuhua Sun, Jingwen Wang, Yuhuan Gao, Xielan Zhao, Kunyan LI, Kaiyang Ding, Zunmin Zhu, Ying Wang, Hongmei Jing, Xiaohong Xu, Xin Wang, Zimin Sun, Da Gao, Wei-LI Zhao
Publikováno v:
HemaSphere, Vol 7, p e1263860 (2023)
Externí odkaz:
https://doaj.org/article/58a4274135b549a0a6c71633dace5b8d
Autor:
Wei Zhang, Liping Su, Lihong Liu, Yuhuan Gao, Quanshun Wang, Hang Su, Yuhuan Song, Huilai Zhang, Jing Shen, Hongmei Jing, Shuye Wang, Xinan Cen, Hui Liu, Aichun Liu, Zengjun Li, Jianmin Luo, Jianxia He, Jingwen Wang, O. A. O’Connor, Daobin Zhou
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 841-848 (2021)
Objective: To assess the efficacy and safety of the novel histone deacetylase inhibitor, chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (Chi-CHOEP) for untreated peripheral T-cell lymphoma (PTCL).
Externí odkaz:
https://doaj.org/article/c398250e5dfc4d54afc4d7f32476965d
Autor:
Yuankai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang, Lin Wang, Weihua Zhang, Huilai Zhang, Liping Xie, Ming Jiang, Hui Zhou, Yuerong Shuang, Hang Su, Xiaoyan Ke, Chuan Jin, Xin Du, Li Liu, Yaming Xi, Zheng Ge, Ru Feng, Yang Zhang, Shengyu Zhou, Fan Xie, Qian Wang
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-13 (2021)
Abstract Background Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety of geptanolimab (GB226
Externí odkaz:
https://doaj.org/article/7e43576f16064c5f8c7daf2c4245a7da
Publikováno v:
Technology in Cancer Research & Treatment, Vol 19 (2020)
In this study we aimed to identify a set of prognostic factors for angioimmunoblastic T-cell lymphoma (AITL) and establish a novel prognostic model. The clinical data of 64 AITL patients enrolled to the Fourth Hospital of Hebei Medical University (fr
Externí odkaz:
https://doaj.org/article/8bdc039f03f549d2ab3c868f5b758cfb
Autor:
Yuankai Shi, Hang Su, Yongping Song, Wenqi Jiang, Xiuhua Sun, Wenbin Qian, Wei Zhang, Yuhuan Gao, Zhengming Jin, Jianfeng Zhou, Chuan Jin, Liqun Zou, Lugui Qiu, Wei Li, Jianmin Yang, Ming Hou, Yan Xiong, Hui Zhou, Xinhua Du, Xiong Wang, Bo Peng
Publikováno v:
EBioMedicine, Vol 54, Iss , Pp - (2020)
Background: Blood-based biomarker such as circulating tumor DNA (ctDNA) has emerged as a promising tool for assessment of response to immunotherapy in solid tumors; But in hematological malignances, evidences are still lacking to support its clinical
Externí odkaz:
https://doaj.org/article/5b545204ff25407485d56cf697fd1121
Autor:
Wen Zheng, Yuhuan Gao, Xiaoyan Ke, Weijing Zhang, Liping Su, Hanyun Ren, Ningjing Lin, Yan Xie, Meifeng Tu, Weiping Liu, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Xiaopei Wang, Yuqin Song, Jun Zhu
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background The combination of chemotherapy and L-asparaginase (L-ASP) treatment significantly increased survival rate in an adult patient with extranodal natural killer (NK)/T-cell lymphoma (NKTCL). However, hypersensitivity reactions of L-A
Externí odkaz:
https://doaj.org/article/a50c652a5cdb4605ad2598127f6c2fee
Autor:
Guangyu, Ma, Yuhuan, Gao, Xiaotong, Jing, Cuiying, He, Haisheng, Liu, Xiaolin, Wu, Zhe, Gao, Yuan, Li, Shengnan, Zhang, Guimin, Zhao
Publikováno v:
Leukemia & Lymphoma. 64:140-150
In the current study, we assessed the relationship between mutations and the blood cell counts and early progression of patients with diffuse large-B cell lymphoma (DLBCL). A total of 109 patients with newly diagnosed DLBCL were included in this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c6bc512a570220a9f41354b3ce6587
https://doi.org/10.1080/10428194.2022.2131427
https://doi.org/10.1080/10428194.2022.2131427
Autor:
Yuankai Shi, Bo Jia, Wei Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang, Xi Zhang, Jie Jin, Zhengming Jin, Zhiming Li, Lugui Qiu, Mei Dong, Xiaobing Huang, Yi Luo, Xiaodong Wang, Xin Wang, Jianqiu Wu, Jingyan Xu, Pingyong Yi, Jianfeng Zhou, Hongming He, Lin Liu, Jianzhen Shen, Xiaoqiong Tang, Jinghua Wang, Jianmin Yang, Qingshu Zeng, Zhihui Zhang, Zhen Cai, Xiequn Chen, Kaiyang Ding, Ming Hou, Huiqiang Huang, Xiaoling Li, Rong Liang, Qifa Liu, Yuqin Song, Hang Su, Yuhuan Gao, Lihong Liu, Jianmin Luo, Liping Su, Zimin Sun, Huo Tan, Huaqing Wang, Jingwen Wang, Shuye Wang, Hongyu Zhang, Xiaohong Zhang, Daobin Zhou, Ou Bai, Gang Wu, Liling Zhang, Yizhuo Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2017)
Abstract The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA)
Externí odkaz:
https://doaj.org/article/fb0461c9c99841929ebde75677646c99